Oncolytics Other Current Liab from 2010 to 2024

ONCY Stock  USD 0.92  0.03  3.16%   
Oncolytics Biotech Other Current Liabilities yearly trend continues to be fairly stable with very little volatility. Other Current Liabilities is likely to outpace its year average in 2024. During the period from 2010 to 2024, Oncolytics Biotech Other Current Liabilities regression line of annual values had r-squared of  0.09 and arithmetic mean of  2,359,133. View All Fundamentals
 
Other Current Liabilities  
First Reported
2000-03-31
Previous Quarter
5.9 M
Current Value
1.3 M
Quarterly Volatility
2.2 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Oncolytics Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oncolytics Biotech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 382.9 K, Interest Expense of 637.6 K or Selling General Administrative of 16.9 M, as well as many indicators such as Price To Sales Ratio of 66.83, Dividend Yield of 0.0 or PTB Ratio of 4.5. Oncolytics financial statements analysis is a perfect complement when working with Oncolytics Biotech Valuation or Volatility modules.
  
Check out the analysis of Oncolytics Biotech Correlation against competitors.
For more information on how to buy Oncolytics Stock please use our How to Invest in Oncolytics Biotech guide.

Latest Oncolytics Biotech's Other Current Liab Growth Pattern

Below is the plot of the Other Current Liab of Oncolytics Biotech over the last few years. It is Oncolytics Biotech's Other Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Oncolytics Biotech's overall financial position and show how it may be relating to other accounts over time.
Other Current Liab10 Years Trend
Slightly volatile
   Other Current Liab   
       Timeline  

Oncolytics Other Current Liab Regression Statistics

Arithmetic Mean2,359,133
Geometric Mean0.00
Coefficient Of Variation146.66
Mean Deviation2,419,764
Median1,477,000
Standard Deviation3,459,809
Sample Variance12T
Range12.5M
R-Value0.30
Mean Square Error11.7T
R-Squared0.09
Significance0.28
Slope232,975
Total Sum of Squares167.6T

Oncolytics Other Current Liab History

20244.3 M
20234.1 M
20221.5 M
20212.4 M
20202.5 M
201912.5 M
201861.3 K

About Oncolytics Biotech Financial Statements

Oncolytics Biotech investors use historical fundamental indicators, such as Oncolytics Biotech's Other Current Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Oncolytics Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Current Liabilities4.1 M4.3 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Oncolytics Stock Analysis

When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.